Figure 1.
Sustained virological response (SVR) rates to sofosbuvir/velapatasvir/voxilaprevir in previous direct acting antiviral fauilures. Sofosbuvir/velpatasvir/voxilaprevir for the re-treatment of direct acting antiviral failures. SVR12, sustained virological response at week 12.